Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glaucoma and Ocular Hypertension Clear all
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT02129673
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C, Latanoprost 0.005% eye drops
Drug
Lead sponsor
ViSci Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 13, 2026, 10:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions

NCT01915680
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure
Interventions
Not listed
Lead sponsor
Robert Ritch, MD, LLC.
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 13, 2026, 10:20 PM EDT
Terminated Phase 1 Interventional

Safety Study of Latanoprost Slow Release Insert

NCT01180062
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Latanoprost, Arm 2, Latanoprost SR insert
Drug
Lead sponsor
Daniel Moore
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 13, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry

NCT04360369
View directory record Official record
Conditions
Intraocular Pressure, Glaucoma
Interventions
IOP with Goldmann Applanation Tonometer, IOP with comparator ORA G3 and ic100 tonometers, IOP with Tono-Vera Tonometer
Device
Lead sponsor
Reichert, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 13, 2026, 10:20 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 13, 2026, 10:20 PM EDT
Completed Phase 1Phase 2 Interventional

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

NCT01654484
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 13, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

NCT00572455
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 13, 2026, 10:20 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

NCT00650338
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Artesia, California • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Oct 13, 2026, 10:20 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)

NCT04271709
View directory record Official record
Conditions
Glaucoma, Vision Impairment and Blindness, Cataract, Diabetic Retinopathy, Eye Diseases
Interventions
Enhanced Intervention Using Patient Navigators, Usual Care
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
749 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 13, 2026, 10:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

NCT00803387
View directory record Official record
Conditions
Ocular Dryness, Ocular Irritation, Open-Angle Glaucoma, Ocular Hypertension
Interventions
Travaprost without BAC (Travatan Z)
Drug
Lead sponsor
United States Air Force
Federal
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2008 · Synced Oct 13, 2026, 10:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Macular Pigment and Visual Performance in Glaucoma Patients

NCT03959592
View directory record Official record
Conditions
Glaucoma
Interventions
Lutein, zeaxanthin and mesozeaxanthin, Placebo
Drug · Other
Lead sponsor
Felipe Medeiros, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Oct 13, 2026, 10:20 PM EDT
Withdrawn Not applicable Interventional

IOP and Medication Reduction in MIGS Procedures

NCT04202510
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions
Glaucoma and Cataract Surgery
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 13, 2026, 10:20 PM EDT
Completed No phase listed Observational

Clinical and Molecular Studies in Families With Glaucoma and Related Diseases

NCT00272363
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
3
States / cities
Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 13, 2026, 10:20 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Outcomes in Cataract Surgery With OMNI Canaloplasty vs Cataract Surgery With OMNI Canaloplasty and Hydrus Stent

NCT05949242
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI canaloplasty, Hydrus microstent
Device
Lead sponsor
Ridge Eye Care
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
4
States / cities
Marysville, California • Oroville, California • Paradise, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 13, 2026, 10:20 PM EDT
Completed No phase listed Observational

Comparison of Gonioscopy With Cirrus and Visante

NCT01895686
View directory record Official record
Conditions
Open Angle Glaucoma, Narrow Angles, Angle Closure Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 13, 2026, 10:20 PM EDT
Completed Not applicable Interventional

Excimer Laser Trabeculostomy Glaucoma Treatment Study

NCT04899063
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
ELIOS Procedure
Device
Lead sponsor
Elios Vision, Inc.
Industry
Eligibility
45 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
20
States / cities
Glendale, Arizona • Petaluma, California • Fort Collins, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 13, 2026, 10:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses

NCT02852057
View directory record Official record
Conditions
Glaucoma
Interventions
timolol maleate and dorzolamide hydrochloride
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 13, 2026, 10:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

NCT06120842
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Glendale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 13, 2026, 10:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 13, 2026, 10:20 PM EDT
Withdrawn Not applicable Interventional

The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma

NCT02524431
View directory record Official record
Conditions
Glaucoma
Interventions
Collection of trabecular meshwork tissue during surgery
Other
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 13, 2026, 10:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Functional and Structural Imaging for Glaucoma

NCT01957267
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 85 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 10:20 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

P200TE Agreement and Precision Study

NCT05536401
View directory record Official record
Conditions
Retina Disease, Glaucoma, Normal
Interventions
P200TE, Predicate Device
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 13, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749930
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 13, 2026, 10:20 PM EDT
Completed No phase listed Observational

The Study of Ocular Hemodynamics With Glaucoma Progression

NCT01145911
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
30 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 13, 2026, 10:20 PM EDT